Close

Merck Statement Regarding FDA Approval of Changes to Trade Packaging Design

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal

Roche-owned Genentech has entered into a major collaboration with...

Treatment for Rare Disease cALD Approved by European Commission

Neuraxpharm and Minoryx Therapeutics have secured European Commission approval...
- Advertisement -

Merck appreciates the U.S. Food and Drug Administration’s (FDA) recognition of our efforts to create new standardized product packaging for several of our medicines.

These changes to the packaging of several medicines were made by Merck as a result of comprehensive research conducted directly with pharmacists and pharmacy technicians to understand how the company could help them to further support the accuracy of medication dispensing within the pharmacy.

Michael Rosenblatt, M.D., chief medical officer for Merck said, Efforts such as this are a part of Merck’s overall commitment to help people be well. We look forward to continuing to work with regulatory agencies and healthcare professionals to implement this new design and help bring the best possible care to patients

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Roche and Earendil Forge $1.5 Billion Bispecific Antibody Discovery Deal

Roche-owned Genentech has entered into a major collaboration with...

Treatment for Rare Disease cALD Approved by European Commission

Neuraxpharm and Minoryx Therapeutics have secured European Commission approval...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »